Final 7-Year Follow-Up Substudy of Using Venetoclax Combined with Rituximab for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
In this final long-term analysis of the groundbreaking MURANO trial, progression-free survival (PFS) and overall survival (OS) benefits for venetoclax-rituximab (VenR) over bendamustine-rituximab (BR) were once again confirmed.